🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. FLUOROURACIL, DOCETAXEL, OPDIVO 10 mg/mL concentrate for solution for infusion., OXALIPLATIN, CALCIUM LEVOFOLINATE, CISPLATIN, DOXORUBICIN HYDROCHLORIDE

    Verona Pharma Ireland Limited

    Gastric adenocarcinoma with peritoneal metastases

    phase 3 small molecule active

    1 trial

  2. FLUOROURACIL, Tecentriq 1 200 mg concentrate for solution for infusion, CALCIUM FOLINATE PENTAHYDRATE, OXALIPLATIN

    The George Institute

    stage III colon adenocarcinoma with deficient MMR

    phase 3 small molecule active

    1 trial

  3. FLUTICASONE , Dupilumab, SALBUTAMOL , BUDESONIDE , MONTELUKAST , Matched placebo for test (dupilumab low dose), Matched placebo for test (dupilumab high dose), BECLOMETASONE , Dupilumab, SALMETEROL AND FLUTICASONE

    Sanofi-aventis Healthcare Pty Ltd

    Respiratory tract diseases - Wheezing, Asthma

    phase 3 small molecule active

    1 trial

  4. FST-201 (dexamethasone 0.1%) Otic Suspension

    Takeda

    Acute Fungal Otitis Externa

    phase 3 small molecule terminated

    1 trial

  5. FST-201 (dexamethasone 0.1%) Otic Suspension

    Takeda

    Acute Otitis Externa

    phase 3 small molecule terminated

    1 trial

  6. FST201 (dexamethasone 0.1% with povidone-iodine 1%)

    Takeda

    Acute Otitis Externa

    phase 3 small molecule completed

    1 trial

  7. FUROSEMIDE , DULOXETINE

    Ningbo Cancer Hospital

    ER positive HER2 negative breast cancer stages I-II

    phase 3 small molecule active

    1 trial

  8. FUROSEMIDE, FUROSEMIDE, FUROSEMIDE, HYDROCHLOROTHIAZIDE

    The George Institute

    Acute Heart Failure

    phase 3 small molecule active

    1 trial

  9. Fabrazyme 35 mg powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671, Replagal 1 mg/ml concentrate for solution for infusion., Replagal 1 mg/ml concentrate for solution for infusion., Galafold 123 mg hard capsules, Replagal 1 mg/ml concentrate for solution for infusion.

    Sanofi-aventis Healthcare Pty Ltd

    Fabry’s disease

    phase 3 small molecule active

    1 trial

  10. Faricimab

    Hoffmann-La Roche

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  11. Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes

    Lxo Ireland Designated Activity Company

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  12. Fasedienol Nasal Spray

    Vistagen Therapeutics

    Social Anxiety Disorder (SAD)

    phase 3 small molecule active

    1 trial

  13. Fasedienol Nasal Spray

    Vistagen Therapeutics

    Social Anxiety Disorder

    phase 3 small molecule active

    1 trial

  14. Fazirsiran Injection

    Takeda

    Alpha1-Antitrypsin Deficiency

    phase 3 small molecule active

    3 trials

  15. Femara 2.5 mg film-coated tablets, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Anastrozole 1mg film-coated tablets, Docetaxel Pfizer 10 mg/mL concentrate for solution for infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Exemestane 25 mg Film-coated Tablets, Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Abraxane 5 mg/ml powder for dispersion for infusion.

    Ningbo Cancer Hospital

    low-grade serous carcinoma of the ovary or peritoneum

    phase 3 small molecule active

    1 trial

  16. Ferric Citrate 1 GM Oral Tablet [AURYXIA]

    Akebia Europe Limited

    Anemia, Iron Deficiency

    phase 3 small molecule completed

    1 trial

  17. Film-Coated Tablet without Deucravacitinib, Film-Coated Tablet without JNJ-77242113, DEUCRAVACITINIB, JNJ-77242113

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  18. Fimasartan and Rosuvastatin

    Yung NA

    Essential Hypertension, Dyslipidemia

    phase 3 small molecule completed

    1 trial

  19. Flecainide or Sotalol or Propafenone

    Rhythm Pharmaceuticals Netherlands B.V.

    Paroxysmal Atrial Fibrillation

    phase 3 small molecule completed

    1 trial

  20. Fluoxetine

    BRIGHT MINDS BIOSCIENCES INC.

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  21. Fluticasone Propionate and Salmeterol Inhalation Powder

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule completed

    1 trial

  22. Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)

    Ultragenyx UK Limited

    Eosinophilic Gastrointestinal Disorders (EGIDs)

    phase 3 small molecule completed

    1 trial

  23. Fluticasone/ Formoterol

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Asthma

    phase 3 small molecule active

    1 trial

  24. Fluzoparib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer Metastatic

    phase 3 small molecule active

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources